# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.
JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $...
- SEC Filing
Vera expects cash position to be sufficient to fund operations through potential approval and us commercial launch of Atacicept...
Wolfe Research analyst Andy Chen downgrades Vera Therapeutics (NASDAQ:VERA) from Outperform to Peer Perform.